Codagenix lands $20 mln Series B
Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding.
Farmingdale, New York-based Codagenix Inc, a developer of prophylactic vaccines and oncolytic virus therapies, has raised $20 million in Series B funding.
Copyright PEI Media
Not for publication, email or dissemination